Page last updated: 2024-08-23

raloxifene hydrochloride and Cardiovascular Diseases

raloxifene hydrochloride has been researched along with Cardiovascular Diseases in 78 studies

Research

Studies (78)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	13 (16.67)	18.2507
2000's	59 (75.64)	29.6817
2010's	5 (6.41)	24.3611
2020's	1 (1.28)	2.80

Authors

Authors	Studies
Gaman, MA; Li, N; Wang, N; Yang, F	1
Connolly, JG; Gagne, JJ	1
Mershon, JL; Schoenfeld, MJ; Stock, JL	1
Lerman, J; Siseles, N	1
Bruce, D; Frick, A; Robinson, J; Rymer, J; Ylikorkala, O	1
de Villiers, TJ	1
Kurtay, G; Oztas, E	1
Mori, S	1
Hsieh, CF; Huang, WF; Lu, PY; Tsai, YW	1
Karwowski, W; Myśliwiec, M; Naumnik, B; Szczepański, M	1
Jordan, VC; Pappas, SG	1
Gnatuk, CL	1
Gluck, O; Maricic, M	3
de Jong, S; Neele, SJ; Netelenbos, JC; Stehouwer, CD; Teerlink, T	1
Anderson, PW; Barrett-Connor, E; Ensrud, KE; Harper, K; Krueger, KA; Mason, TM; Sashegyi, A	1
Genazzani, AR; Mannella, P; Simoncini, T	1
Draper, MW	1
Kalofoutis, A; Kalofoutis, C; Papapanagiotou, A; Piperi, C; Skenderi, C	1
Guyot, B; This, P	1
Itabashi, A	2
Coombes, RC; Lam, EW; Palmieri, C; Vigushin, D	1
Economidou, O; Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K	1
Barrett-Connor, E; Blackwell, T; Davidowitz, N; Kanaya, AM; Krueger, K; Yaffe, K	1
Delmas, PD; Kulkarni, PM; Plouffe, L; Silverman, SL; Stock, JL; Wong, M	1
Cauley, JA; Johnell, O; Kulkarni, PM; Stock, JL; Wong, M	1
Cerquetani, E; Fini, M; Mercuro, G; Rosano, GM; Vitale, C; Zoncu, S	1
Higuchi, T; Mizunuma, H	1
Mijatovic, V; van der Mooren, MJ; Vogelvang, TE	1
D'Amico, EA; Dias, AR; Gebara, OC; Halbe, HW; Melo, RN; Nussbacher, A; Pinotti, JA	1
Barrett-Connor, E; Keech, CA; Sashegyi, A	1
Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K; Zisaki, K	1
Cano, A; Hermenegildo, C; Oviedo, PJ; Tarín, JJ	1
Boscaro, M; Francucci, CM; Romagni, P	1
Simorre, B	1
Kozakiewicz, K; Wycisk, A	1
Wenger, NK	1
Chan, YC; Huang, Y; Leung, FP; Leung, HS; Tsang, SY; Wong, CM; Yao, X; Yung, LM	1
Abu Fanne, R; Brzezinski, A; Danenberg, HD	1
Nakamura, T	1
Okazaki, R	1
Bryant, HU; Cox, MB; Draper, MW; Hol, T	1
Anderson, PW; Farmer, M; Kuller, LH; Lawrence, JB; Paul, S; Shah, AS; Walsh, BW; Wild, RA	1
Rifkind, BM; Rossouw, JE	1
Anderson, PW; Barrett-Connor, E; Collins, P; Cox, DA; Grady, D; Kornitzer, M; Mosca, L; Moscarelli, E; Wenger, NK	1
Brockie, J	1
de Valk-de Roo, GW; Kenemans, P; Mijatovic, V; Netelenbos, C; van der Mooren, MJ	1
Kenemans, P; Mijatovic, V; Netelenbos, JC; Stehouwer, CD; van der Mooren, MJ	1
Agnusdei, D	1
Hart, W; Netelenbos, JC	1
Chlebowski, RT; Collyar, DE; Pfister, DG; Somerfield, MR	1
Miller, VM	1
Boyce, EG; Parks, SM; Rinaldi, C; Umland, EM	1
Guzzo, JA	1
Jurida, N; Pávó, I; Szúcs, J	1
Cefalu, CA	1
O'Regan, RM	1
Birkhäuser, MH	1
Grossman, LD	1
Blumenthal, R; Bush, TL; Clarkson, TB; Lobo, R	1
Eiken, PA; Kønig, KB; Schwarz, P	1
Godsland, IF	1
Anderson, PW; Cox, DA; Dean, RA; Sashegyi, A; Tracy, RP; Walsh, BW	1
Mijatovic, V; van der Mooren, MJ	1
Walsh, BW	1
Mosca, L	1
Kenemans, P; Mijatovic, V; Neele, SJ; Netelenbos, JC; Smolders, RG; van Baal, WM; van der Mooren, MJ; Vogelvang, TE	1
Anderson, PW; Barrett-Connor, E; Cox, DA; Grady, D; Harper, KD; Hoszowski, K; Rautaharju, P; Sashegyi, A	1
Chondros, C; Christodoulakos, G; Creatsas, G; Dendrinos, S; Kouskouni, E; Panoulis, C	1
Emons, G; Westphalen, S	1
Anthony, M; Arun, B; Dunn, B	1
Burger, H	1
Mayer, DF	1
Dominguez, JE; Shortle, B; Warren, MP	1

Reviews

43 review(s) available for raloxifene hydrochloride and Cardiovascular Diseases

Article	Year
Raloxifene has favorable effects on the lipid profile in women explaining its beneficial effect on cardiovascular risk: A meta-analysis of randomized controlled trials. Pharmacological research, 2021, Volume: 166 Topics: Cardiovascular Diseases; Dyslipidemias; Estrogen Antagonists; Heart Disease Risk Factors; Humans; Lipid Metabolism; Lipids; Protective Factors; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	2021
[Hormone replacement therapy and cardiovascular prevention. Where are we now?]. Medicina, 2008, Volume: 68, Issue:3 Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Myocardial Infarction; Progestins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Women's Health	2008
Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. Climacteric : the journal of the International Menopause Society, 2009, Volume: 12 Suppl 1 Topics: Cardiovascular Diseases; Female; Humans; Indoles; Postmenopause; Pyrrolidines; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism	2009
[Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases]. Clinical calcium, 2011, Volume: 21, Issue:5 Topics: Adrenergic beta-Antagonists; Animals; Cardiovascular Diseases; Diabetes Complications; Diphosphonates; Dyslipidemias; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Life Style; Osteogenesis; Osteoporosis; Raloxifene Hydrochloride; Thiazolidinediones; Vitamin D	2011
The mechanism of vascular calcification - a systematic review. Medical science monitor : international medical journal of experimental and clinical research, 2012, Volume: 18, Issue:1 Topics: Atherosclerosis; Calciphylaxis; Cardiovascular Diseases; Gonadal Steroid Hormones; Heart Valves; Humans; Metabolic Diseases; Models, Biological; Osteoporosis; Raloxifene Hydrochloride; Vascular Calcification	2012
The controversy over estrogen replacement therapy: an update on clinical trials. Current women's health reports, 2002, Volume: 2, Issue:2 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2002
Raloxifene: recent information on skeletal and non-skeletal effects. Current opinion in rheumatology, 2002, Volume: 14, Issue:4 Topics: Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Uterus	2002
[Cardiovascular effects of selective estrogen receptor modulators. Current perspectives]. Recenti progressi in medicina, 2003, Volume: 94, Issue:2 Topics: Aged; Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Cells, Cultured; Clinical Trials as Topic; Cohort Studies; Endothelium, Vascular; Estrogen Antagonists; Female; Follow-Up Studies; Hormone Replacement Therapy; Humans; Middle Aged; Placebos; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors	2003
The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Annals of the New York Academy of Sciences, 2003, Volume: 997 Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Selective Estrogen Receptor Modulators; Treatment Outcome; United States; Women's Health	2003
[Raloxifene and breast: from the SERMs concept to its place in clinical practice]. Gynecologie, obstetrique & fertilite, 2004, Volume: 32, Issue:1 Topics: Aged; Animals; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2004
[MORE study(raloxifene)]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Biomarkers; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Multicenter Studies as Topic; Osteocalcin; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Venous Thrombosis	2004
[Raloxifene hydrochloride]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62 Suppl 2 Topics: Arteriosclerosis; Bone Density; Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
[Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases]. Clinical calcium, 2004, Volume: 14, Issue:10 Topics: Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Venous Thrombosis	2004
Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treatments in endocrinology, 2004, Volume: 3, Issue:2 Topics: Aging; Animals; Arteriosclerosis; Cardiovascular Diseases; Cardiovascular System; Estrogen Replacement Therapy; Female; Humans; Menopause; Middle Aged; Norpregnenes; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2004
Skeletal and nonskeletal effects of raloxifene. Current osteoporosis reports, 2003, Volume: 1, Issue:3 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Spontaneous; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prognosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Severity of Illness Index; Spinal Fractures; Treatment Outcome	2003
Raloxifene: bone and cardiovascular effects. Journal of endocrinological investigation, 2005, Volume: 28, Issue:10 Suppl Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cardiovascular System; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators	2005
[Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 2006, Volume: 59, Issue:5-6 Topics: Cardiovascular Diseases; Estrogen Antagonists; Estrogens; Female; Hormone Replacement Therapy; Humans; Longitudinal Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2006
[Menopausal hormone therapy and cardiovascular disease]. Revista espanola de cardiologia, 2006, Volume: 59, Issue:10 Topics: Age Factors; Aged; Breast Neoplasms; Cardiovascular Diseases; Cohort Studies; Coronary Angiography; Coronary Disease; Electrocardiography; Estrogen Replacement Therapy; Estrogens; Female; Follow-Up Studies; Heart Rate; Humans; Life Style; Mammography; Meta-Analysis as Topic; Middle Aged; Myocardial Infarction; Progestins; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Stroke; Time Factors	2006
Raloxifene, tamoxifen and vascular tone. Clinical and experimental pharmacology & physiology, 2007, Volume: 34, Issue:8 Topics: Animals; Atherosclerosis; Blood Vessels; Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Circulation; Collateral Circulation; Coronary Circulation; Endothelium, Vascular; Estrogen Replacement Therapy; Female; Humans; Nitric Oxide; Pulmonary Circulation; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Vasodilation	2007
Raloxifene: cardiovascular considerations. Mini reviews in medicinal chemistry, 2007, Volume: 7, Issue:8 Topics: Cardiovascular Diseases; Cardiovascular System; Female; Humans; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2007
[Adverse events of drugs for the treatment of osteoporosis]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Oct-28, Volume: 65 Suppl 8 Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Cholecalciferol; Diphosphonates; Gastrointestinal Diseases; Hot Flashes; Humans; Hypercalcemia; Jaw Diseases; Macular Edema; Necrosis; Osteoporosis; Raloxifene Hydrochloride; Venous Thrombosis	2007
[Effects of SERM on the cardiovascular system]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9 Topics: Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Hyperlipidemias; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Stroke	2007
Selective estrogen receptor modulators and postmenopausal women's health. Journal of women's health, 1997, Volume: 6, Issue:5 Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Women's Health	1997
Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. Journal of women's health, 1998, Volume: 7, Issue:7 Topics: Cardiovascular Diseases; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	1998
Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:6 Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Estrogens; Estrogens, Non-Steroidal; Female; Humans; Isoflavones; Menopause; Osteoporosis; Phytoestrogens; Piperidines; Plant Preparations; Raloxifene Hydrochloride; Receptors, Estrogen; Survivors	1999
Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 1999, Volume: 13, Issue:2 Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Endothelium, Vascular; Estrogen Antagonists; Estrogens; Female; Hemostasis; Homocysteine; Hormone Replacement Therapy; Humans; Lipoprotein(a); Muscle, Smooth, Vascular; Piperidines; Progestins; Raloxifene Hydrochloride; Risk Factors	1999
Clinical efficacy of raloxifene in postmenopausal women. European journal of obstetrics, gynecology, and reproductive biology, 1999, Volume: 85, Issue:1 Topics: Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic	1999
[Selective estrogen-receptor modulators (SERM's) in postmenopausal women]. Nederlands tijdschrift voor geneeskunde, 1999, Aug-28, Volume: 143, Issue:35 Topics: Aged; Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	1999
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6 Topics: Anticarcinogenic Agents; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cataract; Endometrial Neoplasms; Estrogen Antagonists; Expert Testimony; Female; Humans; Incidence; Menopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen	1999
The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. The Annals of pharmacotherapy, 1999, Volume: 33, Issue:12 Topics: Aged; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Genital Neoplasms, Female; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride	1999
Selective estrogen receptor modulators--a new age of estrogens in cardiovascular disease? Clinical cardiology, 2000, Volume: 23, Issue:1 Topics: Adult; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
[Clinical experience with raloxifene]. Orvosi hetilap, 2000, Jan-30, Volume: 141, Issue:5 Topics: Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2000
Chemoprevention of breast cancer. Cancer treatment and research, 2000, Volume: 103 Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Bone and Bones; Breast Diseases; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Endometrial Neoplasms; Estrogens; Female; Gonadal Steroid Hormones; Humans; Lipids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Neoplastic Syndromes, Hereditary; Osteoporosis, Postmenopausal; Pilot Projects; Precancerous Conditions; Premenopause; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproductive History; Risk Factors; Safety; Selective Estrogen Receptor Modulators; Tamoxifen	2000
[Indications for hormone replacement therapy]. Therapeutische Umschau. Revue therapeutique, 2000, Volume: 57, Issue:10 Topics: Aged; Alzheimer Disease; Anabolic Agents; Breast Neoplasms; Cardiovascular Diseases; Contraindications; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Female; Humans; Middle Aged; Norpregnenes; Osteoporosis, Postmenopausal; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Thrombosis	2000
SERMs and cardiovascular disease in women. How do these agents affect risk? Postgraduate medicine, 2001, Volume: Spec No Topics: Blood Coagulation Factors; Cardiovascular Diseases; Estrogens, Non-Steroidal; Female; Glycine max; Humans; Isoflavones; Lipid Metabolism; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2001
[SERM--selective estrogen receptor modulators]. Ugeskrift for laeger, 2001, Apr-09, Volume: 163, Issue:15 Topics: Aged; Bone Marrow; Breast; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Estrogen Antagonists; Female; Humans; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertility and sterility, 2001, Volume: 75, Issue:5 Topics: Anabolic Agents; Apolipoproteins; Apoprotein(a); Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Humans; Lipoprotein(a); Middle Aged; Norpregnenes; Progestins; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triglycerides	2001
Homocysteine in postmenopausal women and the importance of hormone replacement therapy. Clinical chemistry and laboratory medicine, 2001, Volume: 39, Issue:8 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Female; Homocysteine; Hormone Replacement Therapy; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Time Factors	2001
The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Cardiovascular Diseases; Estrogen Receptor Modulators; Estrogen Replacement Therapy; Female; Humans; Menopause; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen	2001
Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Adenocarcinoma; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
The search for the ideal SERM. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:6 Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Cognition; Estrogens; Female; Humans; Neoplasms, Hormone-Dependent; Osteoporosis; Postmenopause; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen	2002
Review of raloxifene and its clinical applications in osteoporosis. Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:6 Topics: Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Uterine Diseases	2002
Use of alternative therapies in menopause. Best practice & research. Clinical obstetrics & gynaecology, 2002, Volume: 16, Issue:3 Topics: Cardiovascular Diseases; Estrogens; Female; Humans; Hypercholesterolemia; Isoflavones; Lignans; Menopause; Middle Aged; Neoplasms; Osteoporosis, Postmenopausal; Phytotherapy; Plant Preparations; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002

Trials

17 trial(s) available for raloxifene hydrochloride and Cardiovascular Diseases

Article	Year
A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2. Climacteric : the journal of the International Menopause Society, 2008, Volume: 11, Issue:6 Topics: Cardiovascular Diseases; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Epoprostenol; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Norethindrone; Norethindrone Acetate; Norpregnenes; Raloxifene Hydrochloride; Thromboxane A2	2008
Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids. Archives of gynecology and obstetrics, 2011, Volume: 283, Issue:1 Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Female; Humans; Lipids; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2011
Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clinical science (London, England : 1979), 2003, Volume: 105, Issue:1 Topics: Analysis of Variance; Arginine; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hysterectomy; Middle Aged; Nitric Oxide Synthase; Postmenopause; Protein Isoforms; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sensitivity and Specificity	2003
Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clinical therapeutics, 2003, Volume: 25, Issue:3 Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Statistics as Topic; Time Factors; Treatment Outcome	2003
Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:1 Topics: Age Factors; Aged; Cardiovascular Diseases; Estrogens; Female; Follow-Up Studies; Greece; Hormone Replacement Therapy; Humans; Lipoproteins, HDL; Middle Aged; Postmenopause; Probability; Raloxifene Hydrochloride; Reference Values; Risk Assessment; Selective Estrogen Receptor Modulators; Treatment Outcome	2004
Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:4 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Triglycerides	2004
Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. The Journal of family practice, 2004, Volume: 53, Issue:10 Topics: Adult; Aged; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Cerebrovascular Disorders; Estrogen Replacement Therapy; Female; Humans; Logistic Models; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures	2004
Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2004, Volume: 18, Issue:6 Topics: Aged; Brachial Artery; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Endothelin-1; Endothelium, Vascular; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Nitrates; Nitrites; Postmenopause; Pulsatile Flow; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Vasodilation	2004
Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. Climacteric : the journal of the International Menopause Society, 2005, Volume: 8, Issue:1 Topics: Adult; Aged; Analysis of Variance; Blood Coagulation; Blood Coagulation Factors; Cardiovascular Diseases; Double-Blind Method; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Fibrinolysis; Humans; Lipids; Middle Aged; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome	2005
Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Current medical research and opinion, 2005, Volume: 21, Issue:1 Topics: Aged; Cardiovascular Diseases; Chi-Square Distribution; Female; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators	2005
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA, 1998, May-13, Volume: 279, Issue:18 Topics: Aged; Analysis of Variance; Blood Coagulation Factors; Cardiovascular Diseases; Double-Blind Method; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Lipoproteins; Medroxyprogesterone Acetate; Middle Aged; Piperidines; Postmenopause; Progesterone Congeners; Prospective Studies; Raloxifene Hydrochloride; Risk Factors	1998
Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause (New York, N.Y.), 1999,Summer, Volume: 6, Issue:2 Topics: Administration, Oral; Analysis of Variance; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Humans; Hysterectomy; Lipoprotein(a); Middle Aged; Piperidines; Postmenopause; Raloxifene Hydrochloride; Treatment Outcome	1999
Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women. The American journal of cardiology, 2001, Oct-01, Volume: 88, Issue:7 Topics: Analysis of Variance; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Estrogen Antagonists; Female; Hormone Replacement Therapy; Humans; Interleukin-6; Middle Aged; Osteoporosis; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risk Factors; Tumor Necrosis Factor-alpha	2001
Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Annals of the New York Academy of Sciences, 2001, Volume: 949 Topics: Adenocarcinoma; Breast Neoplasms; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2001
A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine. Maturitas, 2002, Feb-26, Volume: 41, Issue:2 Topics: Cardiovascular Diseases; Double-Blind Method; Estrogens, Conjugated (USP); Female; Homocysteine; Hormone Replacement Therapy; Humans; Lipoprotein(a); Medroxyprogesterone Acetate; Middle Aged; Prospective Studies; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA, 2002, Feb-20, Volume: 287, Issue:7 Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Ischemic Attack, Transient; Lipoproteins; Myocardial Ischemia; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Stroke; Survival Analysis	2002
Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2002, Volume: 16, Issue:1 Topics: Cardiovascular Diseases; Double-Blind Method; Endothelin-1; Epoprostenol; Estradiol; Estrogen Replacement Therapy; Female; Humans; Middle Aged; Nitric Oxide; Norethindrone; Norethindrone Acetate; Placebos; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2002

Other Studies

19 other study(ies) available for raloxifene hydrochloride and Cardiovascular Diseases

Article	Year
Comparison of Calipers for Matching on the Disease Risk Score. American journal of epidemiology, 2016, 05-15, Volume: 183, Issue:10 Topics: Aged; Aged, 80 and over; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Computer Simulation; Cyclooxygenase 2 Inhibitors; Epidemiologic Methods; Ezetimibe; Female; Gastrointestinal Hemorrhage; Humans; Male; Medicare; Models, Theoretical; Monte Carlo Method; Odds Ratio; Osteoporotic Fractures; Prognosis; Propensity Score; Raloxifene Hydrochloride; Risk Assessment; Simvastatin; United States	2016
Review of comparative effectiveness of treatments to prevent fractures. Annals of internal medicine, 2008, Jun-03, Volume: 148, Issue:11 Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Clinical Trials as Topic; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride	2008
Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clinical therapeutics, 2011, Volume: 33, Issue:9 Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Osteoporosis; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risk; Taiwan	2011
Raloxifene for the treatment and prevention of breast cancer? Expert review of anticancer therapy, 2001, Volume: 1, Issue:3 Topics: Breast Neoplasms; Cardiovascular Diseases; Female; Humans; Lipids; Osteoporosis; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Uterus	2001
ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators. Obstetrics and gynecology, 2002, Volume: 100, Issue:4 Topics: Bone Resorption; Breast Neoplasms; Cardiovascular Diseases; Endometrium; Female; Genitalia, Female; Hot Flashes; Humans; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism	2002
Value of SERMs in postmenopausal women. Lancet (London, England), 2004, May-01, Volume: 363, Issue:9419 Topics: Bone Density; Cardiovascular Diseases; Estrogen Replacement Therapy; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2004
Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology, 2004, Aug-24, Volume: 63, Issue:4 Topics: Age Factors; Aged; Blood Glucose; Brain; Cardiovascular Diseases; Cognition Disorders; Comorbidity; Dementia; Depression; Diabetes Mellitus; Fasting; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Magnetic Resonance Imaging; Middle Aged; Obesity; Odds Ratio; Osteoporosis, Postmenopausal; Prediabetic State; Psychological Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Tomography, X-Ray Computed	2004
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:9 Topics: Age Distribution; Aged; Bone Density; Breast Neoplasms; Calcium; Cardiovascular Diseases; Female; Global Health; Hip Fractures; Humans; Incidence; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Selection; Population Surveillance; Prevalence; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Spinal Fractures; Vitamin D	2004
Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2005, Volume: 25, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Acids; Female; Heptanoic Acids; Humans; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Risk; Treatment Outcome	2005
Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women. Fertility and sterility, 2005, Volume: 84, Issue:6 Topics: Antioxidants; Biomarkers; Cardiovascular Diseases; F2-Isoprostanes; Female; Humans; Middle Aged; Neutrophils; Oxidative Stress; Peroxidase; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2005
[41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece]. La Revue de medecine interne, 2006, Volume: 27, Issue:4 Topics: Aged; Albuminuria; Antihypertensive Agents; Bone Density Conservation Agents; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Pioglitazone; Prospective Studies; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Spironolactone; Thiazolidinediones; Time Factors	2006
Of designer drugs, magic bullets, and gold standards. JAMA, 1998, May-13, Volume: 279, Issue:18 Topics: Cardiovascular Diseases; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens; Humans; Piperidines; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	1998
Using SERMS for treating postmenopausal symptoms. Community nurse, 1999, Volume: 4, Issue:12 Topics: Aged; Cardiovascular Diseases; Estrogen Antagonists; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Piperidines; Postmenopause; Raloxifene Hydrochloride; Tamoxifen	1999
Gender, estrogen, and NOS: cautions about generalizations. Circulation research, 1999, Nov-26, Volume: 85, Issue:11 Topics: Animals; Cardiovascular Diseases; Estrogens; Female; Hormone Replacement Therapy; Humans; Isoenzymes; Macaca fascicularis; Male; Menstrual Cycle; Neutrophils; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Rabbits; Raloxifene Hydrochloride; Receptors, Estrogen; Sex Characteristics; Species Specificity; Transsexualism	1999
Raloxifene therapy in the reduction of fractures. American family physician, 2000, Mar-01, Volume: 61, Issue:5 Topics: Aged; Blood Coagulation Factors; Bone Density; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Estrogen Receptor Modulators; Female; Fractures, Bone; Humans; Incidence; Lipids; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome	2000
Drug information needs clarification. Canadian family physician Medecin de famille canadien, 2001, Volume: 47 Topics: Aged; Cardiovascular Diseases; Clinical Trials as Topic; Estrogen Antagonists; Female; Fractures, Bone; Humans; Menopause; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Reproducibility of Results; Risk Factors	2001
[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Alzheimer Disease; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Primary Prevention; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis; Time Factors	2002
Raloxifene and cardiovascular disease. Climacteric : the journal of the International Menopause Society, 2002, Volume: 5, Issue:2 Topics: Cardiovascular Diseases; Female; Humans; Patient Selection; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Selective Estrogen Receptor Modulators	2002
Raloxifene and risk of cardiovascular events. JAMA, 2002, Jul-03, Volume: 288, Issue:1 Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators	2002